Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy

Heart transplantation is the «gold standard» of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the  availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been  largely responsible for the progressive developmen...

Full description

Saved in:
Bibliographic Details
Main Authors: N. N. Koloskova, E. A. Nikitina, V. M. Zakharevich, I. I. Muminov, V. S. Cvan, V. N. Poptsov, R. L. Ahmadzai, D. A. Izotov, A. O. Shevchenko
Format: Article
Language:Russian
Published: Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov 2018-09-01
Series:Вестник трансплантологии и искусственных органов
Subjects:
Online Access:https://journal.transpl.ru/vtio/article/view/914
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849691247696936960
author N. N. Koloskova
E. A. Nikitina
V. M. Zakharevich
I. I. Muminov
V. S. Cvan
V. N. Poptsov
R. L. Ahmadzai
D. A. Izotov
A. O. Shevchenko
author_facet N. N. Koloskova
E. A. Nikitina
V. M. Zakharevich
I. I. Muminov
V. S. Cvan
V. N. Poptsov
R. L. Ahmadzai
D. A. Izotov
A. O. Shevchenko
author_sort N. N. Koloskova
collection DOAJ
description Heart transplantation is the «gold standard» of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the  availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been  largely responsible for the progressive development of renal dysfunction and  reduces long-term patient survival. Use mTOR inhibitor in immunosuppressive  therapy may improve renal function when everolimus is administered associated  with a progressive reduction of CNIs. The purpose of our report is to demonstrate  the successful case of conversion of the recipient after heart transplantation to  everolimus and to evaluate the effectiveness of this drug during the observation year after heart transplantation.
format Article
id doaj-art-20e0463f890042049d270e6bbcd4f6a0
institution DOAJ
issn 1995-1191
language Russian
publishDate 2018-09-01
publisher Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
record_format Article
series Вестник трансплантологии и искусственных органов
spelling doaj-art-20e0463f890042049d270e6bbcd4f6a02025-08-20T03:21:06ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovВестник трансплантологии и искусственных органов1995-11912018-09-01203707410.15825/1995-1191-2018-3-70-74723Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapyN. N. Koloskova0E. A. Nikitina1V. M. Zakharevich2I. I. Muminov3V. S. Cvan4V. N. Poptsov5R. L. Ahmadzai6D. A. Izotov7A. O. Shevchenko8V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)Heart transplantation is the «gold standard» of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the  availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been  largely responsible for the progressive development of renal dysfunction and  reduces long-term patient survival. Use mTOR inhibitor in immunosuppressive  therapy may improve renal function when everolimus is administered associated  with a progressive reduction of CNIs. The purpose of our report is to demonstrate  the successful case of conversion of the recipient after heart transplantation to  everolimus and to evaluate the effectiveness of this drug during the observation year after heart transplantation.https://journal.transpl.ru/vtio/article/view/914heart transplantationimmunosuppressive therapynephrotoxicity of calcineurin inhibitorrenal dysfunctionеverolimusmtor inhibitor
spellingShingle N. N. Koloskova
E. A. Nikitina
V. M. Zakharevich
I. I. Muminov
V. S. Cvan
V. N. Poptsov
R. L. Ahmadzai
D. A. Izotov
A. O. Shevchenko
Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
Вестник трансплантологии и искусственных органов
heart transplantation
immunosuppressive therapy
nephrotoxicity of calcineurin inhibitor
renal dysfunction
еverolimus
mtor inhibitor
title Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
title_full Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
title_fullStr Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
title_full_unstemmed Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
title_short Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
title_sort conversion to everolimus to preserve kidney function in a heart transplant recipient a personalized approach of immunos uppressive therapy
topic heart transplantation
immunosuppressive therapy
nephrotoxicity of calcineurin inhibitor
renal dysfunction
еverolimus
mtor inhibitor
url https://journal.transpl.ru/vtio/article/view/914
work_keys_str_mv AT nnkoloskova conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT eanikitina conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT vmzakharevich conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT iimuminov conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT vscvan conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT vnpoptsov conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT rlahmadzai conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT daizotov conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy
AT aoshevchenko conversiontoeverolimustopreservekidneyfunctioninahearttransplantrecipientapersonalizedapproachofimmunosuppressivetherapy